Cancer mTOR Inhibitors Market By Type ( Afinitor/Votubia, Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor, Torisel (Temsirolimus), Evertor andndash ), By Application ( Breast Cancer, Hematological Malignancy, Neuroendocrine Tumors, Hepatocellular Carcinoma, Glioblastoma ), By Stent Size ( 18 mm, 20 mm, 14 mm ), Industry Trends, Estimation & Forecast, 2017 - 2025

Market Overview:

mTOR, also called as Mammalian target of rapamycin (mTOR), is a member of the phosphatidylinositol 3-kinase-related kinase family of protein kinases. This Kinase functions as a master switch between catabolic and anabolic metabolism and as such is a target for the design of anticancer agents. With the continuous studies and researches in medical science, It is now well-established that mTOR plays a pivotal role in governing cell growth and proliferation, hence making mTOR a therapeutic target for disease conditions caused by deregulated cell proliferation, such as cancer. Since the past two decades, mTOR inhibitors have been developed dedicatedly and a majority of them are still being used for curing Cancer. The most developed mTOR inhibitor called as rapamycin has depicted considerable response to tumors and has substantially improved the survival of patients suffering with renal cell carcinoma.

On the basis of Geography, North America and Europe have emerged out as the largest markets for these inhibitors, owing to the increased awareness among people and large number of diagnosis done for cancers. As per Centers for Disease Control & Prevention, cancer kills more than half a million Americans. Cancer is the second leading cause of death in the United States. One of every four deaths in the United States is due to cancer. Initiatives taken by governments in EU and North America for the treatment of Cancer is giving a push to the mTOR Inhibitor market.

The report provides detailed qualitative and quantitative analysis of the Cancer mTOR Inhibitors Market. Market size and forecast in terms of value and volume has been provided for the period – (2017 – 2025), for the segments namely product and application in each of the major regions.

Cancer mTOR Inhibitors Market Segmentation

By Type
• Afinitor/Votubia
• Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
• Torisel (Temsirolimus)
• Evertor andndash

By Application
• Breast Cancer
• Hematological Malignancy
• Neuroendocrine Tumors
• Hepatocellular Carcinoma
• Glioblastoma

By Geography

 • North America
o U.S.
o Canada
o Mexico

• Europe
o U.K.
o France
o Germany
o Italy
o Spain
o Rest of Europe

• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of APAC

• South America
o Brazil
o Rest of South America

• Rest of the World
o Middle East
o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC desk research
1.1.2. ERC data synthesis
1.1.3. Data validation and market feedback
1.1.4. ERC data sources

CHAPTER 2. CANCER MTOR INHIBITORS MARKET OVERVIEW
2.1. CANCER MTOR INHIBITORS MARKET INTRODUCTION
2.2. GLOBAL CANCER MTOR INHIBITORS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
2.2.1. Global Cancer mTOR Inhibitors Production (VOLUME) and Growth Rate (%), (2017-2025)
2.3. GLOBAL CANCER MTOR INHIBITORS MARKET CAPACITY AND GROWTH RATE, 2017-2025
2.3.1. Global Cancer mTOR Inhibitors Capacity (VOLUME) and Growth Rate (%), (2017-2025)
2.4. GLOBAL CANCER MTOR INHIBITORS MARKET REVENUE AND GROWTH RATE, 2017-2025
2.4.1. Global Cancer mTOR Inhibitors Market Revenue (Million USD) and Growth Rate (%), (2017-2025)
2.5. GLOBAL CANCER MTOR INHIBITORS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
2.5.1. Global Cancer mTOR Inhibitors Consumption (VOLUME) and Growth Rate (%), (2017-2025)
2.6. GLOBAL CANCER MTOR INHIBITORS MARKET PRICE TREND, 2017-2025
2.6.1. Global Cancer mTOR Inhibitors Market Price Trend and Growth Rate (%), (2017-2025)

CHAPTER 3. GLOBAL CANCER MTOR INHIBITORS MARKET BY TYPE, 2017-2025
3.1. AFINITOR/VOTUBIA
3.2. AFINITOR DISPERZ ANDNDASH; MTOR INHIBITOR FOR RARE PEDIATRIC BRAIN TUMOR
3.3. TORISEL (TEMSIROLIMUS)
3.4. EVERTOR ANDNDASH
3.5. GLOBAL CANCER MTOR INHIBITORS MARKET REVENUE BY TYPE, 2017-2025
3.5.1. Global Cancer mTOR Inhibitors Market Revenue (Million USD) and Share (%) By Type, 2017-2025
3.5.2. Afinitor/Votubia Market Revenue and Growth Rate, 2017-2025
3.5.3. Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Market Revenue and Growth Rate, 2017-2025
3.5.4. Torisel (Temsirolimus) Market Revenue and Growth Rate, 2017-2025

Note: Similar information coverage has been provided for other type segment.

3.5. GLOBAL CANCER MTOR INHIBITORS MARKET PRODUCTION BY TYPE, 2017-2025
3.5.1. Global Cancer mTOR Inhibitors Market Production (Volume) and Share (%) By Type, 2017-2025
3.5.2. Afinitor/Votubia Market Production and Growth Rate, 2017-2025
3.5.3. Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Market Production and Growth Rate, 2017-2025
3.5.4. Torisel (Temsirolimus) Market Production and Growth Rate, 2017-2025

Note: Similar information coverage has been provided for other type segment.

CHAPTER 4. GLOBAL CANCER MTOR INHIBITORS MARKET BY APPLICATION, 2017-2025
4.1. BREAST CANCER
4.2. HEMATOLOGICAL MALIGNANCY
4.3. NEUROENDOCRINE TUMORS
4.4. HEPATOCELLULAR CARCINOMA
4.5. GLIOBLASTOMA
4.6. GLOBAL CANCER MTOR INHIBITORS MARKET REVENUE BY APPLICATION, 2017-2025
4.6.1. Global Cancer mTOR Inhibitors Market Revenue (Million USD) and Share (%) By Application, 2017-2025
4.6.2. Breast Cancer Market Revenue and Growth Rate, 2017-2025
4.6.3. Hematological Malignancy Market Revenue and Growth Rate, 2017-2025
4.6.4. Neuroendocrine Tumors Market Revenue and Growth Rate, 2017-2025
4.7. GLOBAL CANCER MTOR INHIBITORS MARKET CONSUMPTION BY APPLICATION, 2017-2025
4.7.1. Global Cancer mTOR Inhibitors Market Consumption (Volume) and share (%) By Application, 2017-2025
4.7.2. Breast Cancer Market Consumption and Growth Rate, 2017-2025
4.7.3. Hematological Malignancy Market Consumption and Growth Rate, 2017-2025
4.7.4. Neuroendocrine Tumors Market Consumption and Growth Rate, 2017-2025

Note: Similar information coverage has been provided for other application segment.

CHAPTER 5. GLOBAL CANCER MTOR INHIBITORS MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. Canada
5.1.3. Mexico
5.2. EUROPE
5.2.1. U.K.
5.2.2. France
5.2.3. Germany
5.2.4. Italy
5.2.5. Spain
5.2.6. Rest of Europe
5.3. ASIA PACIFIC
5.3.1. China
5.3.2. Japan
5.3.3. India
5.3.4. Korea
5.3.5. Rest of APAC
5.4. SOUTH AMERICA
5.4.1. Brazil
5.4.2. Rest of South America
5.5. REST OF THE WORLD
5.5.1. Middle East
5.5.2. Africa
5.6. GLOBAL CANCER MTOR INHIBITORS MARKET REVENUE BY REGION, 2017-2025
5.6.1. Global Cancer mTOR Inhibitors Market Revenue (Million USD) and Share (%) By Region, 2017-2025
5.6.2. North America Market Revenue and Growth Rate, 2017-2025
5.6.3. Europe Market Revenue and Growth Rate, 2017-2025
5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025
5.6.5. South America Market Revenue and Growth Rate, 2017-2025
5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

CHAPTER 6. GLOBAL CANCER MTOR INHIBITORS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
6.1. GLOBAL CANCER MTOR INHIBITORS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
6.1.1. Global Cancer mTOR Inhibitors Market Production (Volume) and Share (%) By Region, 2017-2025
6.1.2. Global Cancer mTOR Inhibitors Market Consumption (Volume) and Share (%) By Region, 2017-2025
6.1.3. North America Market Production and Consumption, 2017-2025
6.1.4. Europe Market Production and Consumption, 2017-2025
6.1.5. Asia Pacific Market Production and Consumption, 2017-2025
6.1.6. South America Market Production and Consumption, 2017-2025
6.1.7. Rest of the World Market Production and Consumption, 2017-2025

CHAPTER 7. MARKET DETERMINANTS
7.1. MARKET DRIVERS
7.2. MARKET RESTRAINTS
7.3. MARKET OPPORTUNITIES
7.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 8. GLOBAL CANCER MTOR INHIBITORS MARKET COMPETITION BY MANUFACTURERS
8.1. GLOBAL CANCER MTOR INHIBITORS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
8.1.1. Global Cancer mTOR Inhibitors Production (VOLUME) and Share (%) by Manufacturers (2017-2025)
8.2. GLOBAL CANCER MTOR INHIBITORS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
8.2.1. Global Cancer mTOR Inhibitors Revenue (Million USD) and Share (%) by Manufacturers (2017-2025)
8.3. CANCER MTOR INHIBITORS MARKET COMPETITIVE SITUATION AND TRENDS
8.3.1. Cancer mTOR Inhibitors Market Share (%) of Top 3 Manufacturers
8.3.2. Cancer mTOR Inhibitors Market Share (%) of Top 5 Manufacturers

CHAPTER 9. GLOBAL CANCER MTOR INHIBITORS MANUFACTURERS ANALYSIS
9.1. ADIMAB
9.1.1. Business Overview
9.1.2. Company Basic Information
9.1.3. Cancer mTOR Inhibitors Product Details
9.1.4. Adimab Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.2. CELATOR PHARMACEUTICALS
9.2.1. Business Overview
9.2.2. Company Basic Information
9.2.3. Cancer mTOR Inhibitors Product Details
9.2.4. Celator Pharmaceuticals Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.3. CELGENE CORPORATION
9.3.1. Business Overview
9.3.2. Company Basic Information
9.3.3. Cancer mTOR Inhibitors Product Details
9.3.4. Celgene Corporation Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.4. ELI LILLY
9.4.1. Business Overview
9.4.2. Company Basic Information
9.4.3. Cancer mTOR Inhibitors Product Details
9.4.4. Eli Lilly Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.5. ABRAXIS BIOSCIENCE
9.5.1. Business Overview
9.5.2. Company Basic Information
9.5.3. Cancer mTOR Inhibitors Product Details
9.5.4. Abraxis BioScience Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.6. WYETH
9.6.1. Business Overview
9.6.2. Company Basic Information
9.6.3. Cancer mTOR Inhibitors Product Details
9.6.4. Wyeth Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.7. EXELIXIS
9.7.1. Business Overview
9.7.2. Company Basic Information
9.7.3. Cancer mTOR Inhibitors Product Details
9.7.4. Exelixis Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.8. GLAXOSMITHKLINE
9.8.1. Business Overview
9.8.2. Company Basic Information
9.8.3. Cancer mTOR Inhibitors Product Details
9.8.4. GlaxoSmithKline Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.9. HEC PHARM
9.9.1. Business Overview
9.9.2. Company Basic Information
9.9.3. Cancer mTOR Inhibitors Product Details
9.9.4. HEC Pharm Cancer mTOR Inhibitors Production, Revenue and Gross Margin
9.10. NOVARTIS
9.10.1. Business Overview
9.10.2. Company Basic Information
9.10.3. Cancer mTOR Inhibitors Product Details
9.10.4. Novartis Cancer mTOR Inhibitors Production, Revenue and Gross Margin

CHAPTER 10. CANCER MTOR INHIBITORS MARKET VALUE CHAIN ANALYSIS
10.1. CANCER MTOR INHIBITORS INDUSTRIAL CHAIN ANALYSIS
10.2. CANCER MTOR INHIBITORS KEY RAW MATERIALS ANALYSIS
10.2.1. Key Raw Materials
10.2.2. Price Trend of Key Raw Materials
10.2.3. Key Suppliers of Raw Materials
10.3. MARKETING CHANNEL
10.3.1. Direct Marketing
10.3.2. Indirect Marketing
10.3.3. Distributors/Traders
10.4. CONSUMER ANALYSIS
10.4.1. Consumer 1
10.4.2. Consumer 2
10.4.3. Consumer 3
10.4.4. Consumer 4

• Adimab
• Celator Pharmaceuticals
• Celgene Corporation
• Eli Lilly
• Wyeth
• Abraxis BioScience
• Exelixis
• GlaxoSmithKline
• HEC Pharm
• Intellikine
• Novartis
• Oneness Biotech
• PIQUR Therapeutics
• Semafore Pharmaceuticals
• Takeda